Genmab reports Q3 net sales of Darzalex

Genmab announced that worldwide net trade sales of Darzalex, including sales of the subcutaneous product, as reported by Johnson & Johnson were $3.016M in Q3. Net trade sales were $1,684M in the U.S. and $1.332M in the rest of the world. Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and SC products, under the exclusive worldwide license to Janssen to develop, manufacture and commercialize daratumumab.